FDA Approves Drug Combo for Metastatic Non-Small Cell Lung Cancer
Approval is for tremelimumab in combination with durvalumab and platinum-based chemotherapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.